Quality of life and emotional distress in sarcoma patients diagnosed during COVID-19 pandemic: a supplementary analysis from the SarCorD study.
COVID-19
aggressive benign musculoskeletal disease
bone sarcoma
quality of life
sarcoma
soft tissue sarcoma
Journal
Frontiers in psychology
ISSN: 1664-1078
Titre abrégé: Front Psychol
Pays: Switzerland
ID NLM: 101550902
Informations de publication
Date de publication:
2023
2023
Historique:
received:
19
11
2022
accepted:
16
05
2023
medline:
19
6
2023
pubmed:
19
6
2023
entrez:
19
6
2023
Statut:
epublish
Résumé
The COVID-19 outbreak had a negative psychological impact on cancer patients. In this study, we analyzed emotional distress and quality of life in patients diagnosed with sarcoma during the first year of the pandemic compared to the previous year. We retrospectively enrolled patients with soft tissue, bone sarcoma, and aggressive benign musculoskeletal diseases diagnosed during the pandemic (COVID group) or the year before (control group) at the IRCCS Regina Elena National Cancer Institute in Rome. Patients who had undergone a psychological assessment with the EORTC QLQ-C30 and the Distress Thermometer at diagnosis were included in the final analysis. We analyzed whether there is a difference in the various domains of quality of life between the two groups and whether there are changes over time in each group. We enrolled 114 patients (72 control group; 42 COVID group), affected by soft tissue (64%), bone sarcoma (29%), and aggressive benign musculoskeletal diseases (7%). We did not observe significant differences in the health-related quality of life domains in the control and COVID groups, except for the financial domain ( We observed a higher level of distress among patients diagnosed during the pandemic compared to the year before, probably due to the increased concern for both infection and cancer, the worsened perception of health status, and the perception of a poorer quality of health care.
Sections du résumé
Background
UNASSIGNED
The COVID-19 outbreak had a negative psychological impact on cancer patients. In this study, we analyzed emotional distress and quality of life in patients diagnosed with sarcoma during the first year of the pandemic compared to the previous year.
Methods
UNASSIGNED
We retrospectively enrolled patients with soft tissue, bone sarcoma, and aggressive benign musculoskeletal diseases diagnosed during the pandemic (COVID group) or the year before (control group) at the IRCCS Regina Elena National Cancer Institute in Rome. Patients who had undergone a psychological assessment with the EORTC QLQ-C30 and the Distress Thermometer at diagnosis were included in the final analysis. We analyzed whether there is a difference in the various domains of quality of life between the two groups and whether there are changes over time in each group.
Results
UNASSIGNED
We enrolled 114 patients (72 control group; 42 COVID group), affected by soft tissue (64%), bone sarcoma (29%), and aggressive benign musculoskeletal diseases (7%). We did not observe significant differences in the health-related quality of life domains in the control and COVID groups, except for the financial domain (
Conclusion
UNASSIGNED
We observed a higher level of distress among patients diagnosed during the pandemic compared to the year before, probably due to the increased concern for both infection and cancer, the worsened perception of health status, and the perception of a poorer quality of health care.
Identifiants
pubmed: 37333608
doi: 10.3389/fpsyg.2023.1078992
pmc: PMC10273400
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1078992Informations de copyright
Copyright © 2023 Onesti, Vari, Minghelli, Nardozza, Rossi, Sperati, Checcucci, Faltyn, Cercato, Cosimati, Salvatori, Biagini, Ciliberto, Ferraresi and Maggi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Future Oncol. 2021 Mar;17(7):817-823
pubmed: 33508959
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Ann Oncol. 2021 Dec;32(12):1520-1536
pubmed: 34500044
Cancers (Basel). 2020 Aug 14;12(8):
pubmed: 32823999
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
Cancer Med. 2022 Sep;11(17):3352-3363
pubmed: 35315588
ESMO Open. 2020 Aug;5(4):
pubmed: 32847836
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Cancer Med. 2021 Jun;10(12):3928-3937
pubmed: 33973411
Curr Oncol. 2021 May 13;28(3):1867-1878
pubmed: 34068441
Int J Environ Res Public Health. 2022 Mar 21;19(6):
pubmed: 35329416
Clin Genitourin Cancer. 2021 Apr;19(2):e63-e68
pubmed: 32863188
Front Oncol. 2022 Sep 20;12:1000056
pubmed: 36249051
Medicina (Kaunas). 2022 Apr 19;58(5):
pubmed: 35629977
Future Oncol. 2019 Sep;15(27):3125-3134
pubmed: 31512484
Sarcoma. 2015;2015:745163
pubmed: 25767410
Cancer. 2021 Oct 1;127(19):3671-3679
pubmed: 34161601
Cancer Rep (Hoboken). 2022 Oct;5(10):e1571
pubmed: 34636178
JCO Glob Oncol. 2021 Feb;7:162-172
pubmed: 33529077
Psychooncology. 2018 Dec;27(12):2740-2746
pubmed: 30171792
J Cancer Surviv. 2017 Feb;11(1):158-165
pubmed: 27761785
JNCI Cancer Spectr. 2020 Nov 05;5(1):pkaa104
pubmed: 33437925
Lancet Oncol. 2017 Aug;18(8):1022-1039
pubmed: 28687376
Ann Oncol. 2021 Nov;32(11):1348-1365
pubmed: 34303806